维甲酸治疗分化型甲状腺癌的研究进展  

Research progress of retinoic acid in treatment of differentiated thyroid carcinoma

作　　者：孙奇玫(综述)[1] 于苏国(审校)[1] 

机构地区：[1]山东滨州医学院附属医院内分泌科,256603

出　　处：《肿瘤研究与临床》2013年第6期424-426,共3页Cancer Research and Clinic

摘　　要：分化型甲状腺癌（DTC）在进展过程中尤其是发生转移时细胞可发生失分化，失分化DTC细胞的形态和功能均发生退行性改变，导致碘摄取能力降低或丧失，使放射性碘（131I）治疗和甲状腺素抑制治疗均无法进行。维甲酸（RA）是维生素A的一种生物活性代谢产物，在许多细胞的形态、分化和增殖过程中扮演重要角色。研究表明RA可诱导失分化的DTC细胞再分化，使其逆转为功能性甲状腺组织，对提高DTC患者的治愈率和生存率具有重要的临床意义。Differentiated thyroid carcinoma （DTC） cells can produce loss of differentiation in the progress of cancer development, especial of metastasis. The morphology and function of loss of differentiation DTC cell both generate degenerative changes, resulting in the reduction or loss of iodine uptake of the radioactive, which make radioactive iodine（13~I） treatment and thyroid hormone suppression therapy inefficient on treating DTC. Retinoic acid（RA） is a biologically active metabolite of vitamin A, which plays an important role in many cell morphology, degree of differentiation and proliferationprocess. Studies have shown that the application of RA can induce the loss differentiation of DTC redifferentiation, make its to reverse for functional thyroid organization. It＂ s important to produce the clinical significance, which can improve the cure rate and survival rate of the DTC patients.

关 键 词：分化性甲状腺癌 维甲酸 失分化 诱导再分化 

分 类 号：R736.1[医药卫生—肿瘤]